19 June 2025

Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases

During EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD). This is an anti-neonatal Fc receptor (FcRn) mAb that reduces circulating IgG, including autoantibodies, by selectively blocking the interaction of IgG with FcRn. A year on at EULAR 2025, data from Phase 2 RCT of efgartigimod, an FcRn-inhibitor were presented in autoantibodies positive, moderate to severe active SjD. In addition to SjD, data from Phase 2 RCT of efgartigimod in inflammatory myopathies was presented.

AI in Early Diagnosis of Giant Cell Arteritis

EULAR 2025 – Day 3 Report Highlights from Day 3 included presentations on imaging in vasculitis, a debate on treatin

Tweet Author

RheumNow

Tweet Content

EULAR 2025 – Day 3 Report Highlights from Day 3 included presentations on imaging in vasculitis, a debate on treating high-risk pre-clinical RA, and EULAR Recommendations on ILD treatment, physical activity for arthritis, the EULAR disease activity score for antiphospholipid https://t.co/FAaj443wPX

Imaging and Early Detection in Psoriatic Arthritis At EULAR 2025, there have been new developments in imaging in PsA.

Tweet Author

RheumNow

Tweet Content

Imaging and Early Detection in Psoriatic Arthritis At EULAR 2025, there have been new developments in imaging in PsA. Two key poster presentations (POS0104 and OP0179) provide important insights into the role of imaging in the management and early detection of psoriatic https://t.co/41fgXj5WnN

Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What makes ?

Tweet Author

RheumNow

Tweet Content

Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/35cWYRehdd

Predictors and Outcomes in Systemic Sclerosis The VEDOSS project has previously shown that 70% of patients with Raynau

Tweet Author

RheumNow

Tweet Content

Predictors and Outcomes in Systemic Sclerosis The VEDOSS project has previously shown that 70% of patients with Raynaud’s phenomenon and at least one red flag – systemic sclerosis (SSc)-specific antibodies, puffy fingers, or an SSc pattern on nailfold capillaroscopy –will https://t.co/9dJn1qMQfy

Multinational metanalyses of 24 studies & 1,173,410 participants shows alcohol increases risk of hyperuricemia (OR 1

Tweet Author

RheumNow

Tweet Content

Multinational metanalyses of 24 studies & 1,173,410 participants shows alcohol increases risk of hyperuricemia (OR 1.51) and gout (OR 1.81) - more so in males > females. Little effect of age, country, study type, type of alcohol, Dx criteria in regression analyses. https://t.co/NSYTppcKzV

Topics

Assessment of Peripheral Arthritis in Spondyloarthritis

Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life

IL17 inhibitors - STAMP T2T and Combinations

AI in Early Diagnosis of Giant Cell Arteritis

EULAR 2025 – Day 3 Report Highlights from Day 3 included presentations on imaging in vasculitis, a debate on treatin

Imaging and Early Detection in Psoriatic Arthritis At EULAR 2025, there have been new developments in imaging in PsA.

Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA At a EULAR 2025 session titled “What makes ?

Predictors and Outcomes in Systemic Sclerosis The VEDOSS project has previously shown that 70% of patients with Raynau

Multinational metanalyses of 24 studies & 1,173,410 participants shows alcohol increases risk of hyperuricemia (OR 1

Do you get our email newsletter?